Sakuranetin reverses vascular peribronchial and lung parenchyma remodeling in a murine model of chronic allergic pulmonary inflammation

• Published in: Acta histochemica Vol. 118; no. 6; pp. 615 - 624
• Main Authors: Sakoda, Camila Pivari Pedroso, de Toledo, Alessandra Choqueta, Perini, Adenir, Pinheiro, Nathalia Montouro, Hiyane, Meire Ioshie, Grecco, Simone dos Santos, de Fátima Lopes Calvo Tibério, Iolanda, Câmara, Niels Olsen Saraiva, de Arruda Martins, Milton, Lago, João Henrique Ghilardi, Righetti, Renato Fraga, Prado, Carla Máximo
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01-07-2016
• Subjects: Animals; Asthma - drug therapy; Asthma - pathology; Bronchial asthma; Chronic Disease; Collagen - metabolism; Disease Models, Animal; Eosinophils - drug effects; Flavonoids - pharmacology; Lung - drug effects; Lung - pathology; Lung parenchyma; Male; Mice, Inbred BALB C; Ovalbumin - metabolism; Oxidative stress; Peribronchial vessels; Pneumonia - drug therapy; Pneumonia - pathology; Remodeling; Sakuranetin; Oxidative stress; Bronchial asthma; Sakuranetin; Remodeling; Lung parenchyma; Peribronchial vessels
• DOI: 10.1016/j.acthis.2016.07.001
• EISSN: 1618-0372
• ISSN: 0065-1281

Asthma is a disease of high prevalence and morbidity that generates high costs in hospitalization and treatment. Although the airway is involved in the physiopathology of asthma, there is also evidence of the importance of vascular and lung parenchyma inflammation and remodeling, which can contribute to the functional pulmonary alterations observed in asthmatic patients. Our aim was to evaluate treatment using sakuranetin, a flavone isolated from the twigs of Baccharis retusa (Asteraceae), on vascular and lung parenchyma alterations in an experimental murine model of asthma.
Male BALB/c mice were subjected to a sensitization protocol with ovalbumin for 30days and were treated with or without sakuranetin (20mg/kg/mice) or dexamethasone (5mg/kg/mice); then, the lungs were collected for histopathological analysis. We evaluated extracellular matrix remodeling (collagen and elastic fibers), inflammation (eosinophils and NF-kB) and oxidative stress (8-isoprostane) in the pulmonary vessels and lung parenchyma. The thickness of the vascular wall was quantified, as well as the vascular endothelial growth factor (VEGF) levels.
We demonstrated that sakuranetin reduced the number of eosinophils and elastic fibers in both the pulmonary vessels and the lung parenchyma, probably due to a reduction of oxidative stress and of the transcription factor NF-kB and VEGF levels in the lung. In addition, it reduced the thickness of the pulmonary vascular wall. The treatment had no effect on the collagen fibers. In most of the parameters, the effect of sakuranetin was similar to the dexamethasone effect.
Sakuranetin had anti-inflammatory and antioxidant effects, preventing vascular and distal parenchyma changes in this experimental model of asthma.